Sign In
Buy SNY
$43.75
-0.230 (-0.523%)
At Close: Jul 21, 2026
Press Release: Update on FDA priority review of Dupixent for the treatment of COPD patients with type 2 inflammation
01:00am, Friday, 31'st May 2024
Update on FDA priority review of Dupixent for the treatment of COPD patients with type 2 inflammation Paris and Tarrytown, NY May 31, 2024. The US Food and Drug Administration (FDA) has extended by th
Press Release: Sanofi completes acquisition of Inhibrx, Inc.
09:01am, Thursday, 30'th May 2024
Sanofi completes acquisition of Inhibrx, Inc. Paris, May 30, 2024. Sanofi announced today the completion of its acquisition of Inhibrx, Inc. (“Inhibrx”).
Sanofi's (SNY) Sarclisa sBLA Gets FDA's Priority Review Tag
11:46am, Monday, 27'th May 2024
The FDA grants priority review to Sanofi's (SNY) sBLA for the Sarclisa combination regimen for transplant-ineligible newly diagnosed multiple myeloma. A decision is due on Sep 27, 2024.
Sarclisa accepted for FDA priority review for the treatment of transplant-ineligible newly diagnosed multiple myeloma FDA Priority Review granted based on positive results from IMROZ phase 3 study If
Bristol Myers, Sanofi liability in Hawaii Plavix case grows to $916 million
12:06pm, Wednesday, 22'nd May 2024
A judge in Hawaii on Tuesday ordered Bristol Myers Squibb and Sanofi to pay more than $916 million to the state for failing to warn non-white patients of health risks from its blood thinner Plavix, up
Sanofi (SNY) Signs Deal for AI-Powered Drug Development
12:56pm, Tuesday, 21'st May 2024
Sanofi (SNY) inks collaboration deal with Formation Bio and OpenAI to build AI-powered software to advance drug development and create new medicines.
Sanofi partners with OpenAI: here's how it will mitigate AI related risks
08:18am, Tuesday, 21'st May 2024
Sanofi SA (EPA: SAN) is in focus today after teaming up with OpenAI to deploy artificial intelligence for drug development.
Sanofi chief on new partnership with OpenAI for AI-driven drug development
07:01am, Tuesday, 21'st May 2024
Emmanuel Frenehard, Executive Vice President and Chief Digital Officer at Sanofi, discusses the company's new partnership with OpenAI and Formation Bio for AI-driven drug development.
Sanofi partners with OpenAI, Formation Bio on AI-driven drug development
01:50am, Tuesday, 21'st May 2024
French drugmaker Sanofi on Tuesday announced it is collaborating with artificial intelligence company OpenAI and Formation Bio to boost its drug development projects through the use of Artificial Inte
Press Release: Sanofi, Formation Bio and OpenAI announce first-in-class AI collaboration
01:30am, Tuesday, 21'st May 2024
Sanofi, Formation Bio and OpenAI announce first-in-class AI collaboration Paris, New York, N.Y., and San Francisco, CA, May 21, 2024.
Press Release: Dupixent® late-breaking data from NOTUS confirmatory phase 3 COPD study presented at ATS and published in NEJM
02:15pm, Monday, 20'th May 2024
Dupixent ® late-breaking data from NOTUS confirmatory phase 3 COPD study presented at ATS and published in NEJM NOTUS results confirm landmark data from the phase 3 BOREAS study and show Dupixent sig
Perosphere Technologies Adds Dr. Michael Grosso to Advisory Board
09:03am, Monday, 20'th May 2024
DANBURY, Conn.--(BUSINESS WIRE)--Perosphere Technologies (Perosphere Technologies Inc.), a private medical technologies company focused on developing next-generation coagulation diagnostics, today ann
Beacon Pointe Advisors LLC Lowers Stock Position in Sanofi (NASDAQ:SNY)
08:04am, Monday, 20'th May 2024
Beacon Pointe Advisors LLC cut its stake in shares of Sanofi (NASDAQ:SNY – Free Report) by 3.1% in the fourth quarter, according to the company in its most recent disclosure with the Securities
Shah Capital ends campaign against Novavax board after Sanofi deal
07:40am, Monday, 20'th May 2024
Hedge fund Shah Capital said on Monday it would withdraw its campaign against the re-election of three directors on Novavax's board, after the COVID-19 vaccine maker struck a licensing deal with Sanof
Novavax stock jumps 50% as Sanofi deal kicks off turning point for struggling vaccine maker
01:37pm, Monday, 13'th May 2024
Novavax said the deal with Sanofi allows it to remove its "going concern" warning, which it first issued last year due to doubts about staying afloat.
